Every day, Pfizer colleagues work to provide improved health outcomes by supporting preventions, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as a World leading biopharmaceutical company, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable and affordable health care for the community. 

Pfizer Anti-Infectives has undertaken to prioritise research, education and drug development initiatives designed to help address the critical need for novel antimicrobial medicines, a better understanding of bacterial antibiotic resistance and projects to enhance antimicrobial stewardship. Please visit us at www.pfizer.com.au

At AstraZeneca Australia & New Zealand, we have been working to deliver life-changing medicines to patients for more than 60 years with over 800 employees across Australia and New Zealand.Our ambition in Vaccines and Immune Therapies is to develop and deliver transformative vaccines and antibodies, providing long-lasting immunity for millions of people where the burden of disease is greatest.  

The pandemic tested our health systems to their limits, systems that were already straining to meet increasing population needs and bridge health inequalities. Change is needed to build healthcare provision that is both resilient and sustainable in the face of long-term stresses. To support this and drive improvements in public health, we are investing in ground-breaking collaborations, local partnerships, commercial initiatives and advanced manufacturing. 

We supplied our COVID-19 vaccine at cost during the pandemic and were the first manufacturer to join COVAX, a facility working for equitable access to COVID-19 vaccines. We are also innovating across our supply chain and manufacturing processes to ensure that we are able to respond to market demand, boosting productivity when needed, while maintaining excellence in product quality and efficiency.

The Institute for Health Transformation, Deakin University, is addressing the 21st century’s most complex and compelling health challenges through excellence in collaborative research that transforms the design and delivery of prevention and care across health systems. We are committed to building knowledge and skills in situational awareness and risk assessment for existing and emerging diseases and evaluating the effectiveness of control measures. Our infectious disease epidemiological and biostatistical research generates, communicates and translates high-quality evidence into public health practice and disease prevention and control strategies to improve public policy and population health.